JP2021514631A5 - - Google Patents

Info

Publication number
JP2021514631A5
JP2021514631A5 JP2020544661A JP2020544661A JP2021514631A5 JP 2021514631 A5 JP2021514631 A5 JP 2021514631A5 JP 2020544661 A JP2020544661 A JP 2020544661A JP 2020544661 A JP2020544661 A JP 2020544661A JP 2021514631 A5 JP2021514631 A5 JP 2021514631A5
Authority
JP
Japan
Prior art keywords
fusion protein
cancer
cell
signaling domain
domain
Prior art date
Application number
JP2020544661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514631A (ja
JPWO2019165116A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019014 external-priority patent/WO2019165116A1/en
Publication of JP2021514631A publication Critical patent/JP2021514631A/ja
Publication of JPWO2019165116A5 publication Critical patent/JPWO2019165116A5/ja
Publication of JP2021514631A5 publication Critical patent/JP2021514631A5/ja
Pending legal-status Critical Current

Links

JP2020544661A 2018-02-26 2019-02-21 細胞免疫療法のための組成物および方法 Pending JP2021514631A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862635450P 2018-02-26 2018-02-26
US62/635,450 2018-02-26
US201862676787P 2018-05-25 2018-05-25
US62/676,787 2018-05-25
US201862739792P 2018-10-01 2018-10-01
US62/739,792 2018-10-01
PCT/US2019/019014 WO2019165116A1 (en) 2018-02-26 2019-02-21 Compositions and methods for cellular immunotherapy

Publications (3)

Publication Number Publication Date
JP2021514631A JP2021514631A (ja) 2021-06-17
JPWO2019165116A5 JPWO2019165116A5 (https=) 2022-03-01
JP2021514631A5 true JP2021514631A5 (https=) 2022-03-01

Family

ID=65818064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544661A Pending JP2021514631A (ja) 2018-02-26 2019-02-21 細胞免疫療法のための組成物および方法

Country Status (7)

Country Link
US (1) US20210079061A1 (https=)
EP (1) EP3759130A1 (https=)
JP (1) JP2021514631A (https=)
CN (1) CN112041335A (https=)
AU (1) AU2019224051A1 (https=)
CA (1) CA3091138A1 (https=)
WO (1) WO2019165116A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US12077598B2 (en) * 2018-03-16 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated CD28 phosphorylation sites
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
JP7439279B2 (ja) * 2020-02-13 2024-02-27 イミュノファーム テクノロジー カンパニー リミテッド キメラ抗原受容体の最適化
BR112022020156A2 (pt) * 2020-04-07 2022-11-22 Univ Health Network Composições e métodos para intensificar a ativação e atividade citolítica de células t cd8+ através do rompimento do complexo saga (spt?ada?gcn5?acetiltransferase
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
EP4185610A2 (en) * 2020-07-21 2023-05-31 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
JP7724010B2 (ja) * 2021-04-08 2025-08-15 イムビラ・バイオファーマシューティカルズ・カンパニー・リミテッド ケモカイン及び腫瘍関連/特異的抗原を送達する遺伝子改変腫瘍溶解性単純ヘルペスウイルス
CN116102658B (zh) * 2021-11-09 2025-04-29 四川大学华西医院 基于gas6构建的嵌合抗原受体免疫细胞制备及其应用
US20250319130A1 (en) * 2022-06-01 2025-10-16 Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute Recombinant receptors binding b cell activation factor receptor and uses thereof
CN117065029A (zh) * 2022-10-31 2023-11-17 徐州医科大学 C1qbp在提高t细胞抗肿瘤能力中的应用
CN118206620A (zh) * 2022-12-09 2024-06-18 上海细胞治疗集团股份有限公司 一种多肽标签及其应用
CN119710010A (zh) * 2025-02-18 2025-03-28 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) Slc7a5在作为宫颈癌的不良预后标志物和/或制备防治宫颈癌药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5525503A (en) * 1993-09-28 1996-06-11 Dana-Farber Cancer Institute, Inc. Signal transduction via CD28
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US20060078552A1 (en) 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
WO2007051077A2 (en) 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
CN102245196B (zh) 2008-12-12 2015-12-02 托莱多大学 新型Na+/K+-ATP酶衍生肽作为新型SRC抑制剂和乌本苷拮抗剂以及它们的治疗作用
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
WO2010124188A1 (en) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
EP2513146B1 (en) 2009-12-18 2017-05-03 Kancera AB Antibodies against ror1 capable of inducing cell death of cll
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス, インコーポレイテッド 新規のdna結合タンパク質及びその使用
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
ES2791716T3 (es) 2010-12-14 2020-11-05 Univ Maryland Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン,エルエルシー 抗b7−h4抗体およびその使用
US9708384B2 (en) 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093718A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
US20160333108A1 (en) * 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JP6943760B2 (ja) 2014-09-12 2021-10-06 ジェネンテック, インコーポレイテッド 抗b7−h4抗体及び免疫複合体
JP2017531427A (ja) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド グルココルチコイド誘導腫瘍壊死因子受容体(gitr)抗体およびその使用法
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
WO2016168769A1 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Chimeric receptor t cell switches for her2
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
EP4043485A1 (en) * 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
JP7141725B2 (ja) * 2017-07-07 2022-09-26 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 変異cd28共刺激ドメインを有するキメラ抗原受容体
CA3070861A1 (en) * 2017-09-22 2019-03-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced nfkb signaling

Similar Documents

Publication Publication Date Title
JP2021514631A5 (https=)
JP7490915B2 (ja) 抗メソテリンキメラ抗原受容体(car)構築物及びその使用
JP2021519580A5 (https=)
AU2021307614B2 (en) Engineered immune cell for allotransplantation
RU2020135106A (ru) Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
JP2022113880A5 (https=)
JP7767502B2 (ja) Nk阻害性分子を発現する遺伝子改変免疫細胞とその使用
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
JP2020511136A5 (https=)
JP2021519301A5 (https=)
JP2020506700A5 (https=)
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
JP2021532742A5 (https=)
JP2017524367A5 (https=)
JPWO2019191339A5 (https=)
JPWO2019165116A5 (https=)
JPWO2019191340A5 (https=)
JP2022524906A (ja) 細胞免疫療法の組み合わせ
JPWO2021173985A5 (https=)
EP4613781A1 (en) Immune rejection-resistant engineered cell
Kim et al. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
WO2024179620A2 (zh) 耐免疫排斥的工程化细胞
JPWO2023044456A5 (https=)
JPWO2021211948A5 (https=)
EP4653524A1 (en) Function-enhanced cell therapy